MedTrace Logo

Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer

NCT04883827 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2024-10-22

No results posted yet for this study

Summary

This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy

Conditions

Interventions

OTHER

Blood collection

20-40 mL of blood to extract cell free DNA

OTHER

Urine collection

up to 15 mL of urine to extract cell free DNA

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • Scott Haake, MD · Vanderbilt Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-06
Primary Completion
2023-12-01
Completion
2023-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04883827 on ClinicalTrials.gov